You are using an outdated browser. Please upgrade your browser to improve your experience.

eribulin

Ligand Summary
Ligand Structure
Rendered image for the query structure
Description
Eribulin inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into nonproductive aggregates. Eribulin exerts its effects via a tubulin-based antimitotic mechanism leading to G2/M cell-cycle block, disruption of mitotic spindles, and, ultimately, apoptotic cell death after prolonged mitotic blockage. In addition, eribulin treatment of human breast cancer cells caused changes in morphology and gene expression as well as decreased migration and invasiveness in vitro. In mouse xenograft models of human breast cancer, eribulin treatment was associated with increased vascular perfusion and permeability in the tumor cores, resulting in reduced tumor hypoxia, and changes in the expression of genes in tumor specimens associated with a change in phenotype.
Synonyms & Links
Guide to Pharmacology: 6813
DrugCentral: 4171
LyCHI:  1BJVJWPGGFZ6


loading...
Target Activities